Summit Therapeutics Inc.
SMMT
$17.47
-$1.44-7.62%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -221.32M | -196.68M | -161.69M | -116.03M | -614.93M |
| Total Depreciation and Amortization | 89.00K | 97.00K | 109.00K | 135.00K | 198.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 63.64M | 58.95M | 44.14M | 18.26M | 538.49M |
| Change in Net Operating Assets | 15.48M | 24.74M | 19.95M | 3.87M | -516.00K |
| Cash from Operations | -142.11M | -112.89M | -97.49M | -93.76M | -76.76M |
| Capital Expenditure | -139.00K | -127.00K | -122.00K | -79.00K | -128.00K |
| Sale of Property, Plant, and Equipment | -- | 0.00 | 0.00 | 226.00K | 226.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -205.20M | -228.13M | -123.00M | 77.01M | -587.87M |
| Cash from Investing | -205.34M | -228.26M | -123.13M | 77.16M | -587.77M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -100.00M | -75.50M | 0.00 | 0.00 | -24.69M |
| Issuance of Common Stock | 481.23M | 487.21M | 207.57M | 7.36M | 112.21M |
| Repurchase of Common Stock | -- | -- | -390.00K | -390.00K | -390.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -619.00K | 0.00 | -80.00K | -619.00K |
| Cash from Financing | 381.23M | 411.09M | 207.18M | 6.89M | 86.51M |
| Foreign Exchange rate Adjustments | -18.00K | 362.00K | 78.00K | 359.00K | 839.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 33.76M | 70.31M | -13.36M | -9.36M | -577.18M |
